Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141797 | 1.00 | CYP19A1 (0.70) | CYP19A1 | |
| Ethylene SCHEMBL28038914 | 0.98 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL28278507 | 0.90 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL9782731 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL9782727 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL4298015 | 0.87 | CYP19A1 (0.69) | CYP19A1 | |
| SCHEMBL7611386 | 0.87 | CYP19A1 (0.69) | CYP19A1 | |
| SCHEMBL29688557 | 0.86 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL28433832 | 0.86 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL5171014 | 0.86 | CYP19A1 (0.64) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119339933-A | Age estimation method based on multidimensional data | 中国科学院北京基因组研究所(国家生物信息中心) | 2025-01-21 | — | — | CN | claimed |
| CN-119324053-A | Model and index for evaluating aging delaying effect of estrogen replacement therapy and application of model and index | 中国科学院北京基因组研究所(国家生物信息中心) | 2025-01-17 | — | — | CN | claimed |
| CN-118858479-A | Kit for simultaneously detecting 90 steroid hormones and metabolites thereof in urine sample, detection method and sample pretreatment method | 中国疾病预防控制中心环境与健康相关产品安全所 | 2024-10-29 | — | — | CN | claimed |
| CN-117030904-B | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117030904-A | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-11-10 | — | — | CN | claimed |
| CN-116270460-A | Self-emulsifying drug delivery system (SEDDS) for ophthalmic drug delivery | 阿勒根公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116143857-A | Preparation method and application of 21-position-iodo-steroid compound | 天津药业研究院股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-113583075-B | Preparation method of medroxyprogesterone | 浙江神洲药业有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-108239133-A | The synthetic method of -17 α -ol -3,20- diketone drugs of -16 Alpha-Methyl of 4- pregnenes | 成都千叶龙华石油工程技术咨询有限公司 | 2018-07-03 | — | — | CN | claimed |
| CN-107257680-A | Self Emulsifying Drug Delivery System (SEDDS) for ophthalmic drug delivery | 阿勒根公司 | 2017-10-17 | — | — | CN | claimed |
| CN-104072647-B | One class halogen containing polymers preparation and its as the method for oxidation reaction catalyst catalysis oxidation alcohol to aldehyde ketone | 华东理工大学 | 2017-06-16 | — | — | CN | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
| US-4323512-A | Process for the preparation of steroidal 17α-arylcarboxylates | SCHERING CORPORATION (US) | 1982-04-06 | — | — | US | claimed |
| US-4221787-A | Esteramide prodrugs of anti-inflammatory corticosteroids | INTERX RESEARCH CORPORATION (US) | 1980-09-09 | — | — | US | claimed |
| JP-61001698-A | — | — | None | — | — | JP | disclosed |
| JP-54157553-A | — | — | None | — | — | JP | disclosed |
| US-3980680-A | Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein | SCHERING CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
| US-3716638-A | 6ALPHA-METHYL-19-NOR-PROGESTERONE AND A PROCESS OF ITS MANUFACTURE | CIBA GEIGY CORP | 1973-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | CYP19A1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.